Comparative Pharmacology
Head-to-head clinical analysis: KENALOG 80 versus SOLU MEDROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG 80 versus SOLU MEDROL.
KENALOG-80 vs SOLU-MEDROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triamcinolone acetonide is a synthetic corticosteroid with potent anti-inflammatory, immunosuppressive, and anti-proliferative effects. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of phospholipase A2, which reduces prostaglandin and leukotriene synthesis. It also suppresses cytokine production and immune cell migration.
Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses inflammatory cytokines and immune cell activity.
60 mg (1.5 mL) intramuscularly (deep IM) as a single dose for allergic/ inflammatory conditions; intra-articular or soft tissue injection: 10-40 mg for large joints, 5-25 mg for medium joints, 2.5-10 mg for small joints; intralesional: up to 1 mg per injection site, repeated as needed.
IV or IM: 10-40 mg methylprednisolone (as sodium succinate) every 4-6 hours; high-dose pulse therapy: 30 mg/kg IV over 30-60 minutes every 4-6 hours for 48-72 hours.
None Documented
None Documented
Terminal elimination half-life: 2–4 hours for triamcinolone acetonide; prolonged in hepatic impairment (up to 6–8 hours).
Terminal elimination half-life: 2.5–3.5 hours. In clinical context, the biologic half-life (suppression of HPA axis) is longer (24–36 hours) due to tissue retention of active metabolites.
Primarily hepatic metabolism followed by renal excretion of inactive metabolites; less than 5% excreted unchanged in urine, with minor biliary/fecal elimination (<2%).
Renal: approximately 80% as metabolites (glucuronide and sulfate conjugates) and unchanged drug; biliary/fecal: less than 5%.
Category C
Category C
Corticosteroid
Corticosteroid